NICE rejects Lilly’s Portrazza, but backs Bayer’s Xofigo and Amgen’s Imlygic
Cost regulators for the NHS in England and Wales have published final guidelines turning down the use of Eli Lilly’s Portrazza to treat lung cancer, but backing Bayer’s Xofigo for prostate cancer and Amgen’s Imlygic for melanoma.
Read More
